Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 2
1949 4
1950 2
1951 2
1952 6
1953 7
1954 3
1955 10
1956 5
1957 8
1958 7
1959 10
1960 8
1961 8
1962 5
1963 13
1964 11
1965 15
1966 6
1967 10
1968 14
1969 19
1970 22
1971 19
1972 12
1973 21
1974 21
1975 28
1976 26
1977 23
1978 25
1979 24
1980 23
1981 29
1982 33
1983 34
1984 50
1985 63
1986 58
1987 68
1988 65
1989 77
1990 111
1991 72
1992 89
1993 97
1994 92
1995 93
1996 89
1997 81
1998 92
1999 82
2000 103
2001 89
2002 101
2003 90
2004 99
2005 103
2006 101
2007 109
2008 126
2009 137
2010 127
2011 119
2012 146
2013 184
2014 147
2015 165
2016 162
2017 154
2018 159
2019 166
2020 188
2021 221
2022 189
2023 189
2024 192
2025 173
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,151 results

Results by year

Filters applied: . Clear all
Page 1
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.
Weber JS, Carlino MS, Khattak A, Meniawy T, Ansstas G, Taylor MH, Kim KB, McKean M, Long GV, Sullivan RJ, Faries M, Tran TT, Cowey CL, Pecora A, Shaheen M, Segar J, Medina T, Atkinson V, Gibney GT, Luke JJ, Thomas S, Buchbinder EI, Healy JA, Huang M, Morrissey M, Feldman I, Sehgal V, Robert-Tissot C, Hou P, Zhu L, Brown M, Aanur P, Meehan RS, Zaks T. Weber JS, et al. Lancet. 2024 Feb 17;403(10427):632-644. doi: 10.1016/S0140-6736(23)02268-7. Epub 2024 Jan 18. Lancet. 2024. PMID: 38246194 Clinical Trial.
Systemic Therapy for Melanoma: ASCO Guideline Update.
Seth R, Agarwala SS, Messersmith H, Alluri KC, Ascierto PA, Atkins MB, Bollin K, Chacon M, Davis N, Faries MB, Funchain P, Gold JS, Guild S, Gyorki DE, Kaur V, Khushalani NI, Kirkwood JM, McQuade JL, Meyers MO, Provenzano A, Robert C, Santinami M, Sehdev A, Sondak VK, Spurrier G, Swami U, Truong TG, Tsai KK, van Akkooi A, Weber J. Seth R, et al. Among authors: weber j. J Clin Oncol. 2023 Oct 20;41(30):4794-4820. doi: 10.1200/JCO.23.01136. Epub 2023 Aug 14. J Clin Oncol. 2023. PMID: 37579248
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study.
Chesney J, Lewis KD, Kluger H, Hamid O, Whitman E, Thomas S, Wermke M, Cusnir M, Domingo-Musibay E, Phan GQ, Kirkwood JM, Hassel JC, Orloff M, Larkin J, Weber J, Furness AJS, Khushalani NI, Medina T, Egger ME, Graf Finckenstein F, Jagasia M, Hari P, Sulur G, Shi W, Wu X, Sarnaik A. Chesney J, et al. Among authors: weber j. J Immunother Cancer. 2022 Dec;10(12):e005755. doi: 10.1136/jitc-2022-005755. J Immunother Cancer. 2022. PMID: 36600653 Free PMC article. Clinical Trial.
Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial.
Kirkwood JM, Del Vecchio M, Weber J, Hoeller C, Grob JJ, Mohr P, Loquai C, Dutriaux C, Chiarion-Sileni V, Mackiewicz J, Rutkowski P, Arenberger P, Quereux G, Meniawy TM, Ascierto PA, Menzies AM, Durani P, Lobo M, Campigotto F, Gastman B, Long GV. Kirkwood JM, et al. Among authors: weber j. Nat Med. 2023 Nov;29(11):2835-2843. doi: 10.1038/s41591-023-02583-2. Epub 2023 Oct 16. Nat Med. 2023. PMID: 37845511 Free PMC article. Clinical Trial.
T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study.
Gainor JF, Patel MR, Weber JS, Gutierrez M, Bauman JE, Clarke JM, Julian R, Scott AJ, Geiger JL, Kirtane K, Robert-Tissot C, Coder B, Tasneem M, Sun J, Zheng W, Gerbereux L, Laino A, Porichis F, Pollard JR, Hou P, Sehgal V, Chen X, Morrissey M, Daghestani HN, Feldman I, Srinivasan L, Frederick JP, Brown M, Aanur P, Meehan R, Burris HA 3rd. Gainor JF, et al. Among authors: weber js. Cancer Discov. 2024 Nov 1;14(11):2209-2223. doi: 10.1158/2159-8290.CD-24-0158. Cancer Discov. 2024. PMID: 39115419 Clinical Trial.
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238.
Larkin J, Del Vecchio M, Mandalá M, Gogas H, Arance Fernandez AM, Dalle S, Cowey CL, Schenker M, Grob JJ, Chiarion-Sileni V, Marquez-Rodas I, Butler MO, Di Giacomo AM, Middleton MR, Lutzky J, de la Cruz-Merino L, Arenberger P, Atkinson V, Hill AG, Fecher LA, Millward M, Nathan PD, Khushalani NI, Queirolo P, Ritchings C, Lobo M, Askelson M, Tang H, Dolfi S, Ascierto PA, Weber J. Larkin J, et al. Among authors: weber j. Clin Cancer Res. 2023 Sep 1;29(17):3352-3361. doi: 10.1158/1078-0432.CCR-22-3145. Clin Cancer Res. 2023. PMID: 37058595 Free PMC article.
Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8+ T cells.
Wang K, Coutifaris P, Brocks D, Wang G, Azar T, Solis S, Nandi A, Anderson S, Han N, Manne S, Kiner E, Sachar C, Lucas M, George S, Yan PK, Kier MW, Laughlin AI, Kothari S, Giles J, Mathew D, Ghinnagow R, Alanio C, Flowers A, Xu W, Tenney DJ, Xu X, Amaravadi RK, Karakousis GC, Schuchter LM, Buggert M, Oldridge D, Minn AJ, Blank C, Weber JS, Mitchell TC, Farwell MD, Herati RS, Huang AC. Wang K, et al. Among authors: weber js. Cancer Cell. 2024 Sep 9;42(9):1582-1597.e10. doi: 10.1016/j.ccell.2024.08.007. Epub 2024 Aug 29. Cancer Cell. 2024. PMID: 39214097 Free PMC article.
Evolutionary trajectories of small cell lung cancer under therapy.
George J, Maas L, Abedpour N, Cartolano M, Kaiser L, Fischer RN, Scheel AH, Weber JP, Hellmich M, Bosco G, Volz C, Mueller C, Dahmen I, John F, Alves CP, Werr L, Panse JP, Kirschner M, Engel-Riedel W, Jürgens J, Stoelben E, Brockmann M, Grau S, Sebastian M, Stratmann JA, Kern J, Hummel HD, Hegedüs B, Schuler M, Plönes T, Aigner C, Elter T, Toepelt K, Ko YD, Kurz S, Grohé C, Serke M, Höpker K, Hagmeyer L, Doerr F, Hekmath K, Strapatsas J, Kambartel KO, Chakupurakal G, Busch A, Bauernfeind FG, Griesinger F, Luers A, Dirks W, Wiewrodt R, Luecke A, Rodermann E, Diel A, Hagen V, Severin K, Ullrich RT, Reinhardt HC, Quaas A, Bogus M, Courts C, Nürnberg P, Becker K, Achter V, Büttner R, Wolf J, Peifer M, Thomas RK. George J, et al. Among authors: weber jp. Nature. 2024 Mar;627(8005):880-889. doi: 10.1038/s41586-024-07177-7. Epub 2024 Mar 13. Nature. 2024. PMID: 38480884 Free PMC article.
Loss of TDP-43 oligomerization or RNA binding elicits distinct aggregation patterns.
Pérez-Berlanga M, Wiersma VI, Zbinden A, De Vos L, Wagner U, Foglieni C, Mallona I, Betz KM, Cléry A, Weber J, Guo Z, Rigort R, de Rossi P, Manglunia R, Tantardini E, Sahadevan S, Stach O, Hruska-Plochan M, Allain FH, Paganetti P, Polymenidou M. Pérez-Berlanga M, et al. Among authors: weber j. EMBO J. 2023 Sep 4;42(17):e111719. doi: 10.15252/embj.2022111719. Epub 2023 Jul 11. EMBO J. 2023. PMID: 37431963 Free PMC article.
Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events.
Fa'ak F, Buni M, Falohun A, Lu H, Song J, Johnson DH, Zobniw CM, Trinh VA, Awiwi MO, Tahon NH, Elsayes KM, Ludford K, Montazari EJ, Chernis J, Dimitrova M, Sandigursky S, Sparks JA, Abu-Shawer O, Rahma O, Thanarajasingam U, Zeman AM, Talukder R, Singh N, Chung SH, Grivas P, Daher M, Abudayyeh A, Osman I, Weber J, Tayar JH, Suarez-Almazor ME, Abdel-Wahab N, Diab A. Fa'ak F, et al. Among authors: weber j. J Immunother Cancer. 2023 Jun;11(6):e006814. doi: 10.1136/jitc-2023-006814. J Immunother Cancer. 2023. PMID: 37328287 Free PMC article.
5,151 results